The role of aldosterone and aldosterone-receptor antagonists in heart failure

Reviews in Cardiovascular Medicine

Volumn 5, Issue 2, 2004, Pages 71-81

  Khan, Nazim Uddin Azam ^a   Movahed, Assad ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Aldosterone; Aldosterone receptor antagonist; Congestive heart failure; Eplerenone; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN; ANGIOTENSIN I; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; COLLAGEN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LISINOPRIL; LOOP DIURETIC AGENT; MESSENGER RNA; NEUROHORMONE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RENIN; SODIUM; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE HEART INFARCTION; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; GYNECOMASTIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; HYPOTENSION; MASTALGIA; MORBIDITY; MORTALITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; STANDARD; SURVIVAL;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; SPIRONOLACTONE;

EID: 3042616446     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999-1008.
2. Swedberg K, Eneroth F, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
3. Khan NU, Movahed A. Role of beta-blockers in congestive heart failure. Congest Heart Fail. 2000;6:299-312.
4. Weber MA, Purdy RE. Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci. 1982;30:2009-2017.
5. MacFayden RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
6. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci. 1998;95:687-692.
7. Duprez DA, DeBuyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
8. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
9. Robert V, Heymes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt induced fibrosis. Hypertension. 1999;33:981-986.
10. Diez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res. 1997;35:202-205.
11. Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327-329.
12. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47-54.
13. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD Genotype. J Am Coll Cardiol. 2001;37:1808-1812.
14. Danser AH, Van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37-48.
15. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
16. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst. 2000;1:342-352.
17. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem. 1998;273:4883-4891.
18. Mellon SH, Deschepper CF. Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res. 1993;629:283-292.
19. Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
20. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993;21:289-295.
21. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
22. Anderson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996;28:162-167.
23. Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest. 1997;99:855-860.
24. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol. 1993;71:3A-11A.
25. Schunkert H, Hense HW, Danser J, et al. Association between circulating components of the renin angiotensin aldosterone system and left ventricular mass. Br Heart J. 1997;77:24-31.
26. Zennaro MC, Farman N, Bonbalet JP, Lombes M. Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab. 1997;82:1345-1352.
27. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
28. Robert V, Silvestre JS, Charlemagne D, et al. Biochemical determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension. 1995;26:971-978.
29. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
30. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension. 1992;19:221-227.
31. Robert V. Van Thiem N, Cheav SL, et al. Increased cardiac type I and III collagen mRNA in aldosterone-salt hypertension. Hypertension. 1994;24:30-36.
32. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848-2853.
33. Host NB, Jensen LT, Bendixen PM, et al. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol. 1995;76:869-873.
34. Jalil JE, Doering CW, Janicki JS, et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 1989;64:1041-1050.
35. Laine GA. Microvascular changes in the heart during chronic arterial hypertension. Circ Res. 1988;62:953-960.
36. Hinglais N, Heudes D, Nicoletti A, et al. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
37. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002;39:258-263.
38. Sigel AV, Centrella M, Eghbali-Webb M. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta1. J Mol Cell Cardiol. 1996;28:1921-1929.
39. Fullerton MJ, Funder JW. Aldosterone regulates collagen output of rat cardiac fibroblasts by up-regulation of endothelin receptors. Endocrinol Soc Proc. 1998;93:511.
40. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
41. Jackson EK. Diuretics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Book Co; 1996:706-711.
42. Barr CS, Hanson J, Kennedy N, et al. The effects of a mineralocorticoid antagonist on myocardial MIBG uptake in congestive heart failure. Circulation. 1993;88:I256.
43. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358.
44. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
45. Brilla CG, Matsubara LS, Weber KT Anti-aldosterone treatment and prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
46. Lacolley F, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by sphonolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662-667.
47. Van Belle E, Banters C, Wernert N, et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res. 1995;29:27-32.
48. Zannad F, Alla F, Dousset B, et al, for the Rales investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700-2706.
49. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
50. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
51. Dahlstrom U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol. 1993;71:29A-33A.
52. Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol. 1993;71:40A-45A.
53. Yee K-M, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
54. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol. 2000;86:649-653.
55. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-1593.
56. Rousseau MF, Gurne O, Duprez D, et al, for the Belgian RALES investigators. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. J Am Coll Cardiol. 2002;40:1596-1601.
57. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
58. Yoshikawa T, Handa S, Anzai T, et al. Early reduction of neurohormonal factors plays a key role in mediating the efficiency of beta-blocker therapy for congestive heart failure. Am Heart J. 1996;131:329-336.
59. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103:1644-1648.
60. Schepkens H, Vanholder R, Billouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
61. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646-656.
62. Pitt B, Perez A, for The Randomized Aldactone Evaluation Study Investigators. The authors reply. N Engl J Med. 2000;342:133-134.
63. Corvol P, Michaud A, Menard J, et al. Antiandrogenic effects of spironolactones: mechanism of action. Endocrinology. 1975;97:52-58.
64. Zillich AJ, Carter BL. Eplerenone: a novel selective aldosterone blocker. Ann Pharmacother. 2002;36:1567-1576.
65. Frierdich G, Schuh J, Brown M, et al. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am J Hypertens. 1998;11:94A.
66. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967-2972.
67. Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose-finding study in patients with heart failure. J Am Coll Cardiol. 1999;33:S188A-S189A.
68. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
69. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.